IMPORTANCE: Bacterial vaginosis (BV) is a common cause of vaginal infection. First-line treatments of BV are metronidazole and clindamycin. Due to the increase in antibiotic resistance, effective nonantibiotic treatments for BV are needed. OBJECTIVE: To examine whether dequalinium chloride, a broad-spectrum antiseptic, is noninferior to oral metronidazole for the treatment of BV. DESIGN, SETTING, AND PARTICIPANTS: This phase 4, multicenter, triple-blind, double-dummy, parallel, noninferiority randomized clinical trial was conducted from July 29, 2021, to August 25, 2022, with a 1-month follow-up. Participants were premenopausal women 18 years or older with BV from 11 gynecologic practices and 1 hospital in Poland, Slovakia, and the Czech. INTERVENTION: Patients were randomized to treatment with dequalinium chloride vaginal tablets (10 mg once daily for 6 days) or oral metronidazole (500 mg twice daily for 7 days). Double-dummy medication kits contained vaginal and oral tablets with placebo and active medication. MAIN OUTCOMES AND MEASURES: The main outcome was the noninferiority margin (of 15 percentage points) in the absolute difference in clinical cure rates between dequalinium chloride and metronidazole 7 to 11 days after start of treatment (visit 1). Noninferiority was met if the lower 95% CI for the difference in clinical cure rate was less than 15 percentage points at visit 1. RESULTS: A total of 147 women (mean [SD] age, 36.7 [9.0] years) were treated with dequalinium chloride (n = 72) or metronidazole (n = 75). The clinical cure rates at visit 1 were 64 of 69 (92.8%) for dequalinium chloride vs 69 of 74 (93.2%) for metronidazole in the intention-to-treat population, whereas in the per-protocol population, cure rates were 54 of 58 (93.1%) for dequalinium chloride vs 48 of 53 (90.6%) for metronidazole. The treatment differences of -0.5 percentage points (95% CI, -10.8 to 9.8 percentage points; P = .002) in the intention-to-treat population and 2.5 percentage points (95% CI, -9.4 to 14.4 percentage points; P = .001) in the per-protocol population confirmed the noninferiority of dequalinium chloride. The tolerability of dequalinium chloride was rated as very good by 30 of 50 patients (60.0%) but only by 21 of 54 (38.9%) for metronidazole. Three patients in the metronidazole group suspended treatment due to an adverse event. CONCLUSIONS AND RELEVANCE: This randomized clinical trial showed that dequalinium chloride was not inferior to metronidazole for the treatment of BV. Dequalinium chloride had a similarly high cure rate but with better tolerability and fewer adverse events. With a similar efficacy to metronidazole and clindamycin, dequalinium chloride warrants consideration as first-line treatment for BV to help reduce antibiotic consumption. TRIAL REGISTRATION: EudraCT: 2020-002489-15.

Gynedur s r o Dubnica nad Váhom Slovakia

Gyneko spol s r o Vsetin Czech Republic

Medinova AG Zurich Switzerland

Prywatny Gabinet Gynekologiczno Zurawica Poland

Komentář v

JAMA Netw Open. 2024 May 1;7(5):e248606. doi: 10.1001/jamanetworkopen.2024.8606. PubMed

Zobrazit více v PubMed

Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505-523. doi:10.1016/j.ajog.2013.05.006 PubMed DOI

Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46(5):304-311. doi:10.1097/OLQ.0000000000000972 PubMed DOI

Chow K, Wooten D, Annepally S, Burke L, Edi R, Morris SR. Impact of (recurrent) bacterial vaginosis on quality of life and the need for accessible alternative treatments. BMC Womens Health. 2023;23(1):112. doi:10.1186/s12905-023-02236-z PubMed DOI PMC

Bilardi JE, Walker S, Temple-Smith M, et al. . The burden of bacterial vaginosis: women’s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One. 2013;8(9):e74378. doi:10.1371/journal.pone.0074378 PubMed DOI PMC

Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22. doi:10.1016/0002-9343(83)91112-9 PubMed DOI

Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29(2):297-301. doi:10.1128/jcm.29.2.297-301.1991 PubMed DOI PMC

Muzny CA, Cerca N, Elnaggar JH, Taylor CM, Sobel JD, Van Der Pol B. State of the art for diagnosis of bacterial vaginosis. J Clin Microbiol. 2023;61(8):e0083722. doi:10.1128/jcm.00837-22 PubMed DOI PMC

Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. 2018 European (IUSTI/WHO) International Union Against Sexually Transmitted Infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258-1272. doi:10.1177/0956462418785451 PubMed DOI

Workowski KA, Bachmann LH, Chan PA, et al. . Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1 PubMed DOI PMC

Farr A, Swidsinski S, Surbek D, et al. . Bacterial vaginosis: guideline of the DGGG, OEGGG and SGGG (S2k-level, AWMF registry No. 015/028, June 2023). Geburtshilfe Frauenheilkd. 2023;83(11):1331-1349. doi:10.1055/a-2169-8539 PubMed DOI PMC

Vieira-Baptista P, Stockdale CK, Sobel J. International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis. Admedic; 2023:198.

Verwijs MC, Agaba SK, Darby AC, van de Wijgert JHHM. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. Am J Obstet Gynecol. 2020;222(2):157.e1-157.e13. doi:10.1016/j.ajog.2019.08.008 PubMed DOI PMC

Armstrong-Buisseret L, Brittain C, Kai J, et al. . Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT. Health Technol Assess. 2022;26(2):1-170. doi:10.3310/ZZKH4176 PubMed DOI

Mauck C, Hillier SL, Gendreau J, et al. . Single-dose, bioadhesive clindamycin 2% gel for bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2022;139(6):1092-1102. doi:10.1097/AOG.0000000000004805 PubMed DOI

Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev. 2009;(3):CD006055. doi:10.1002/14651858.CD006055.pub2 PubMed DOI

Bradshaw CS, Pirotta M, De Guingand D, et al. . Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. PLoS One. 2012;7(4):e34540. doi:10.1371/journal.pone.0034540 PubMed DOI PMC

Muzny CA, Sobel JD. The role of antimicrobial resistance in refractory and recurrent bacterial vaginosis and current recommendations for treatment. Antibiotics (Basel). 2022;11(4):500. doi:10.3390/antibiotics11040500 PubMed DOI PMC

Swidsinski A, Mendling W, Loening-Baucke V, et al. . An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97.e1-97.e6. doi:10.1016/j.ajog.2007.06.039 PubMed DOI

Rosca AS, Castro J, França Â, Vaneechoutte M, Cerca N. Gardnerella vaginalis dominates multi-species biofilms in both pre-conditioned and competitive in vitro biofilm formation models. Microb Ecol. 2022;84(4):1278-1287. doi:10.1007/s00248-021-01917-2 PubMed DOI

Della Casa V, Noll H, Gonser S, Grob P, Graf F, Pohlig G. Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforschung. 2002;52(9):699-705. PubMed

D’Auria FD, Simonetti G, Strippoli V. Antimicrobial characteristics of a tincture of dequalinium chloride. Article in Italian. Ann Ig. 1989;1(5):1227-1241. PubMed

Lopes dos Santos Santiago G, Grob P, Verstraelen H, Waser F, Vaneechoutte M. Susceptibility testing of Atopobium vaginae for dequalinium chloride. BMC Res Notes. 2012;5:151. doi:10.1186/1756-0500-5-151 PubMed DOI PMC

Babbs M, Collier HO, Austin WC, Potter MD, Taylor EP. Salts of decamethylene-bis-4-aminoquinaldinium (dequadin); a new antimicrobial agent. J Pharm Pharmacol. 1956;8(2):110-119. PubMed

Roddie TW. Clinical evaluation of dequadin in the treatment of vaginal infections & infestations. Med J Malaya. 1958;13(2):171-172. PubMed

Mendling W, Weissenbacher ER, Gerber S, Prasauskas V, Grob P. Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet. 2016;293(3):469-484. doi:10.1007/s00404-015-3914-8 PubMed DOI PMC

Donders G, Bellen G, Donders F, et al. . Improvement of abnormal vaginal flora in Ugandan women by self-testing and short use of intravaginal antimicrobials. Eur J Clin Microbiol Infect Dis. 2017;36(4):731-738. doi:10.1007/s10096-016-2856-9 PubMed DOI

Antoni Vives J, Cancelo MJ, Losada MA, Doménech A. Dequalinium chloride use in adult Spanish women with bacterial vaginosis: an observational study. J Obstet Gynaecol. 2022;42(1):103-109. doi:10.1080/01443615.2020.1867966 PubMed DOI

Weissenbacher ER, Donders G, Unzeitig V, et al. ; Fluomizin Study Group . A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest. 2012;73(1):8-15. doi:10.1159/000332398 PubMed DOI

Petersen EE, Weissenbacher ER, Hengst P, et al. . Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study. Arzneimittelforschung. 2002;52(9):706-715. PubMed

Eckel F, Farr A, Deinsberger J, Kernmayer-Farr K, Foessleitner P. Dequalinium chloride for the treatment of vulvovaginal infections: a systematic review and meta-analysis. J Low Genit Tract Dis. 2024;28(1):76-83. doi:10.1097/LGT.0000000000000790 PubMed DOI PMC

Portuguese Society of Gynecology (SPG) . Revisão dos Consensos em Infecções Vulvovaginais [Guidelines on the Treatment of Vaginal Infections]. SPG; 2012.

Sociedad Española de Ginecología y Obstetricia (SEGO) . Diagnóstico y tratamiento de las infecciones vulvovaginales: actualizado 2016. Prog Obstet Ginecol. 2016;59(5):350-362.

Zimmer M, Huras H, Kaminski P, et al. . Polish Society of Gynecologists and Obstetricians recommendation on the use of antiseptics for treatment of inflammatory vaginitis. Ginekol Pol. 2020;91(7):432-437. doi:10.5603/GP.2020.0104 PubMed DOI

Gaspar C, Rolo J, Cerca N, Palmeira-de-Oliveira R, Martinez-de-Oliveira J, Palmeira-de-Oliveira A. Dequalinium chloride effectively disrupts bacterial vaginosis (BV) Gardnerella spp. biofilms. Pathogens. 2021;10(3):261. doi:10.3390/pathogens10030261 PubMed DOI PMC

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053 PubMed DOI

US Food and Drug Administration. Bacterial vaginosis: developing drugs for treatment guidance for industry. US Food and Drug Admnistration. Accessed April 12, 2024. August 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacterial-vaginosis-developing-drugs-treatment-guidance-industry

Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group . Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594-2604. doi:10.1001/jama.2012.87802 PubMed DOI

Lugo-Miro VI, Green M, Mazur L. Comparison of different metronidazole therapeutic regimens for bacterial vaginosis: a meta-analysis. JAMA. 1992;268(1):92-95. doi:10.1001/jama.1992.03490010094036 PubMed DOI

Hanson JM, McGregor JA, Hillier SL, et al. . Metronidazole for bacterial vaginosis: a comparison of vaginal gel vs. oral therapy. J Reprod Med. 2000;45(11):889-896. PubMed

Schmitt C, Sobel JD, Meriwether C. Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol. 1992;79(6):1020-1023. PubMed

Paavonen J, Mangioni C, Martin MA, Wajszczuk CP. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol. 2000;96(2):256-260. doi:10.1097/00006250-200008000-00019 PubMed DOI

Larsson PG, Forsum U. Bacterial vaginosis: a disturbed bacterial flora and treatment enigma. APMIS. 2005;113(5):305-316. doi:10.1111/j.1600-0463.2005.apm_113501.x PubMed DOI

US Food and Drug Administration. Non-Inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry. US Food and Drug Administration; 2016. Accessed March 14, 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-inferiority-clinical-trials

Walker J. Non-inferiority statistics and equivalence studies. BJA Educ. 2019;19(8):267-271. doi:10.1016/j.bjae.2019.03.004 PubMed DOI PMC

Kim K, Zeraatkar D, Pitre TS, et al. ; Retina Evidence and Trials INternational Alliance (R.E.T.I.N.A.) Study Group . Noninferiority randomised trials in ophthalmology. Eye (Lond). 2023;37(15):3059-3060. doi:10.1038/s41433-023-02465-4 PubMed DOI PMC

Hillier SL, Austin M, Macio I, Meyn LA, Badway D, Beigi R. Diagnosis and treatment of vaginal discharge syndromes in community practice settings. Clin Infect Dis. 2021;72(9):1538-1543. doi:10.1093/cid/ciaa260 PubMed DOI PMC

Sha BE, Chen HY, Wang QJ, Zariffard MR, Cohen MH, Spear GT. Utility of Amsel criteria, Nugent score, and quantitative PCR for Gardnerella vaginalis, Mycoplasma hominis, and Lactobacillus spp. for diagnosis of bacterial vaginosis in human immunodeficiency virus-infected women. J Clin Microbiol. 2005;43(9):4607-4612. doi:10.1128/JCM.43.9.4607-4612.2005 PubMed DOI PMC

Chen HM, Chang TH, Lin FM, et al. . Vaginal microbiome variances in sample groups categorized by clinical criteria of bacterial vaginosis. BMC Genomics. 2018;19(suppl 10):876. doi:10.1186/s12864-018-5284-7 PubMed DOI PMC

Li T, Zhang Z, Wang F, et al. . Antimicrobial susceptibility testing of metronidazole and clindamycin against Gardnerella vaginalis in planktonic and biofilm formation. Can J Infect Dis Med Microbiol. 2020;2020:1361825. doi:10.1155/2020/1361825 PubMed DOI PMC

Nyirjesy P, McIntosh MJ, Steinmetz JI, Schumacher RJ, Joffrion JL. The effects of intravaginal clindamycin and metronidazole therapy on vaginal Mobiluncus morphotypes in patients with bacterial vaginosis. Sex Transm Dis. 2007;34(4):197-202. doi:10.1097/01.olq.0000235152.98601.d7 PubMed DOI

Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis. 2009;36(11):732-734. doi:10.1097/OLQ.0b013e3181b08456 PubMed DOI

Surapaneni S, Akins R, Sobel JD. Recurrent bacterial vaginosis: an unmet therapeutic challenge. experience with a combination pharmacotherapy long-term suppressive regimen. Sex Transm Dis. 2021;48(10):761-765. doi:10.1097/OLQ.0000000000001420 PubMed DOI PMC

Balkus JE, Carter KA, McClelland RS. Lessons from suppressive therapy and periodic presumptive treatment for bacterial vaginosis. Curr Infect Dis Rep. 2019;21(10):34. doi:10.1007/s11908-019-0688-3 PubMed DOI

Balkus JE, Srinivasan S, Anzala O, et al. . Impact of periodic presumptive treatment for bacterial vaginosis on the vaginal microbiome among women participating in the preventing vaginal infections trial. J Infect Dis. 2017;215(5):723-731. doi:10.1093/infdis/jiw622 PubMed DOI PMC

Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract. 1995;41(5):443-449. PubMed

Johnson M. Clindamycin: An Overview. UpToDate. Accessed April 4, 2023. https://www.uptodate.com/contents/clindamycin-an-overview?search=clindamycin&source=search_result&selectedTitle=2~145&usage_type=default&display_rank=1

Jeng HS, Yan TR, Chen JY. Treating vaginitis with probiotics in non-pregnant females: a systematic review and meta-analysis. Exp Ther Med. 2020;20(4):3749-3765. doi:10.3892/etm.2020.9090 PubMed DOI PMC

Chieng WK, Abdul Jalal MI, Bedi JS, et al. . Probiotics, a promising therapy to reduce the recurrence of bacterial vaginosis in women? a systematic review and meta-analysis of randomized controlled trials. Front Nutr. 2022;9:938838. doi:10.3389/fnut.2022.938838 PubMed DOI PMC